TY - JOUR KW - Aniline Compounds KW - Anti-Infective Agents KW - Humans KW - Imines KW - leprosy KW - Phenazines KW - Sulfonamides KW - Sulfones KW - Thalidomide KW - Urea AU - Convit J AU - Browne S G AU - Languillon J AU - Pettit J H AU - Ramanujam K AU - Sagher F AU - Sheskin J AU - Tarabini G AU - DE SOUZA LIMA L AU - Tolentino J G AU - Waters M F AU - Bechelli L M AU - Martinez Dominguez V AB -
The latest developments and ideas in the therapy of leprosy are discussed, the need for long-term studies being stressed. The therapeutic efficacy and effective dosages of some sulfones (especially diaphenylsulfone), thiambutosine and long-acting sulfonamides such as sulfamethoxine and sulfalene, are considered. The possibilities for two newer drugs, 4,4'-diacetyldiaminodiphenylsulfone and clofazimine (B-663), both still in the early stages of evaluation, are also described and the potential value of thalidomide in treatment of the lepra reaction is discussed. The authors make a number of recommendations for controlled trials and lines of investigation and, in particular, favour a biochemical approach to the correction of defective host defences. Diaphenylsulfone is still considered the drug of choice for use in the therapy of leprosy.
BT - Bulletin of the World Health Organization C1 - http://www.ncbi.nlm.nih.gov/pubmed/5311056?dopt=Abstract CN - CONVIT1970 DA - 1970 IS - 5 J2 - Bull. World Health Organ. LA - eng N2 -The latest developments and ideas in the therapy of leprosy are discussed, the need for long-term studies being stressed. The therapeutic efficacy and effective dosages of some sulfones (especially diaphenylsulfone), thiambutosine and long-acting sulfonamides such as sulfamethoxine and sulfalene, are considered. The possibilities for two newer drugs, 4,4'-diacetyldiaminodiphenylsulfone and clofazimine (B-663), both still in the early stages of evaluation, are also described and the potential value of thalidomide in treatment of the lepra reaction is discussed. The authors make a number of recommendations for controlled trials and lines of investigation and, in particular, favour a biochemical approach to the correction of defective host defences. Diaphenylsulfone is still considered the drug of choice for use in the therapy of leprosy.
PY - 1970 SP - 667 EP - 72 T2 - Bulletin of the World Health Organization TI - Therapy of leprosy. VL - 42 SN - 0042-9686 ER -